MicroRNA-181a Inhibits Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Progression by Repressing CARD11
Danxia Zhu1, Cheng Fang1, Wenting He1
1Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Insights
MicroRNA-181a (miR-181a) suppresses diffuse large B-cell lymphoma (DLBCL) by targeting CARD11. Lower miR-181a levels in ABC-like DLBCL correlate with higher CARD11, promoting tumor growth and invasiveness.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous non-Hodgkin lymphoma.
- Activated B-cell-like (ABC) DLBCL is associated with a poorer prognosis compared to germinal center B-cell-like (GCB) DLBCL.
- MicroRNAs (miRNAs) play crucial roles in cancer development and progression.
Purpose of the Study:
- To investigate the role of miR-181a in DLBCL pathogenesis.
- To identify potential target genes of miR-181a in DLBCL.
- To elucidate the mechanism by which miR-181a affects ABC-like DLBCL.
Main Methods:
- Quantitative real-time PCR to measure miR-181a and CARD11 expression.
- Cell culture and transfection of DLBCL cell lines (OCI-LY10, U2932).
- Overexpression of miR-181a and CARD11, dual luciferase reporter assays, and nude mouse xenograft models.
Main Results:
- miR-181a levels were significantly lower in ABC-like DLBCL cells compared to GCB-like DLBCL cells.
- Overexpression of miR-181a in ABC-like DLBCL cells led to cell cycle arrest, increased apoptosis, and reduced invasiveness.
- CARD11 was identified as a direct target of miR-181a, and its repression by miR-181a inhibited ABC-like DLBCL growth and metastasis in vitro and in vivo.
Conclusions:
- miR-181a functions as a tumor suppressor in ABC-like DLBCL.
- The miR-181a/CARD11 axis is a critical regulator of ABC-like DLBCL progression.
- Targeting miR-181a or its downstream effectors may offer a therapeutic strategy for DLBCL.
Abstract:
We investigated the role of miR-181a in diffuse large B-cell lymphoma (DLBCL) and its potential target genes. miR-181a levels were lower in activated B-cell- (ABC-) like DLBCL cells than that in germinal center B-cell- (GCB-) like DLBCL cells. Overexpression of miR-181a in ABC-like DLBCL cell lines (OCI-LY10 and U2932) resulted in G0/G1 cell cycle arrest, increased apoptosis, and decreased invasiveness. miRNA target prediction programs (miRanda, TargetScan, and miRDB) identified caspase recruitment domain-containing protein 11 (CARD11) as a putative miR-181a target. CARD11 mRNA and protein levels were higher in the ABC-like DLBCL than that in GCB-like DLBCL. Moreover, CARD11 mRNA and protein levels were downregulated in the OCI-LY10 and U2932 cell lines overexpressing miR-181a. Dual luciferase reporter assays confirmed the miR-181a binding site in the CARD11 3'UTR region. OCI-LY10 and U2932 cells transfected with a CARD11 expression vector encoding miR-181a with a mutated binding site showed higher CARD11 protein levels, cell viability, G2/M phase cells, and invasiveness compared to those transfected with a wild-type CARD11 expression vector. Nude mice xenografted with OCI-LY10 cells with overexpressed wild-type miR-181a generated smaller tumors compared to those with overexpressed mutated binding site of CARD11 3'UTR and miR-181a. These results indicate that miR-181a inhibits ABC-like DLBCL by repressing CARD11.
Related Concept Videos
MicroRNAs
MicroRNAs
Abnormal Proliferation
The Intrinsic Apoptotic Pathway


